La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano

Translated title of the contribution: Therapy with aspirin in primary cardiovascular prevention. Italian inter-society consensus document

Massimo Volpe, Maurizio Giuseppe Abrignani, Claudio Borghi, Sergio Coccheri, Paolo Gresele, Giuseppe Patti, Bruno Trimarco, Raffaele De Caterina

Research output: Contribution to journalArticle

Abstract

The indications for the use of aspirin in primary cardiovascular prevention continue to be a source of intense debate, with major international guidelines providing conflicting advices. This document, written by delegates of the main Italian scientific societies dealing with cardiovascular prevention and modeled on a similar document by the European Society of Cardiology Working Group on Thrombosis, reviews the evidence in favor and against the use of aspirin therapy in primary prevention based on data cumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, this document argues for a pragmatic approach to the use of low-dose aspirin in primary cardiovascular prevention, and suggests its use in patients at high cardiovascular risk, defined as ≥2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding.

Original languageItalian
Pages (from-to)442-451
Number of pages10
JournalGiornale Italiano di Cardiologia
Volume15
Issue number7-8
Publication statusPublished - 2014

Fingerprint

Primary Prevention
Aspirin
Therapeutics
Thrombosis
Stroke
Myocardial Infarction
Guidelines
Hemorrhage
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Volpe, M., Abrignani, M. G., Borghi, C., Coccheri, S., Gresele, P., Patti, G., ... De Caterina, R. (2014). La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano. Giornale Italiano di Cardiologia, 15(7-8), 442-451.

La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano. / Volpe, Massimo; Abrignani, Maurizio Giuseppe; Borghi, Claudio; Coccheri, Sergio; Gresele, Paolo; Patti, Giuseppe; Trimarco, Bruno; De Caterina, Raffaele.

In: Giornale Italiano di Cardiologia, Vol. 15, No. 7-8, 2014, p. 442-451.

Research output: Contribution to journalArticle

Volpe, M, Abrignani, MG, Borghi, C, Coccheri, S, Gresele, P, Patti, G, Trimarco, B & De Caterina, R 2014, 'La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano', Giornale Italiano di Cardiologia, vol. 15, no. 7-8, pp. 442-451.
Volpe, Massimo ; Abrignani, Maurizio Giuseppe ; Borghi, Claudio ; Coccheri, Sergio ; Gresele, Paolo ; Patti, Giuseppe ; Trimarco, Bruno ; De Caterina, Raffaele. / La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano. In: Giornale Italiano di Cardiologia. 2014 ; Vol. 15, No. 7-8. pp. 442-451.
@article{c54f24cbf0384159b635ae0c345fe8bb,
title = "La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano",
abstract = "The indications for the use of aspirin in primary cardiovascular prevention continue to be a source of intense debate, with major international guidelines providing conflicting advices. This document, written by delegates of the main Italian scientific societies dealing with cardiovascular prevention and modeled on a similar document by the European Society of Cardiology Working Group on Thrombosis, reviews the evidence in favor and against the use of aspirin therapy in primary prevention based on data cumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, this document argues for a pragmatic approach to the use of low-dose aspirin in primary cardiovascular prevention, and suggests its use in patients at high cardiovascular risk, defined as ≥2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding.",
keywords = "Aspirin, Bleeding, Cancer, Death, Myocardial infarction, Primary prevention",
author = "Massimo Volpe and Abrignani, {Maurizio Giuseppe} and Claudio Borghi and Sergio Coccheri and Paolo Gresele and Giuseppe Patti and Bruno Trimarco and {De Caterina}, Raffaele",
year = "2014",
language = "Italian",
volume = "15",
pages = "442--451",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "7-8",

}

TY - JOUR

T1 - La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di consenso intersocietario Italiano

AU - Volpe, Massimo

AU - Abrignani, Maurizio Giuseppe

AU - Borghi, Claudio

AU - Coccheri, Sergio

AU - Gresele, Paolo

AU - Patti, Giuseppe

AU - Trimarco, Bruno

AU - De Caterina, Raffaele

PY - 2014

Y1 - 2014

N2 - The indications for the use of aspirin in primary cardiovascular prevention continue to be a source of intense debate, with major international guidelines providing conflicting advices. This document, written by delegates of the main Italian scientific societies dealing with cardiovascular prevention and modeled on a similar document by the European Society of Cardiology Working Group on Thrombosis, reviews the evidence in favor and against the use of aspirin therapy in primary prevention based on data cumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, this document argues for a pragmatic approach to the use of low-dose aspirin in primary cardiovascular prevention, and suggests its use in patients at high cardiovascular risk, defined as ≥2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding.

AB - The indications for the use of aspirin in primary cardiovascular prevention continue to be a source of intense debate, with major international guidelines providing conflicting advices. This document, written by delegates of the main Italian scientific societies dealing with cardiovascular prevention and modeled on a similar document by the European Society of Cardiology Working Group on Thrombosis, reviews the evidence in favor and against the use of aspirin therapy in primary prevention based on data cumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, this document argues for a pragmatic approach to the use of low-dose aspirin in primary cardiovascular prevention, and suggests its use in patients at high cardiovascular risk, defined as ≥2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding.

KW - Aspirin

KW - Bleeding

KW - Cancer

KW - Death

KW - Myocardial infarction

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84906888413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906888413&partnerID=8YFLogxK

M3 - Articolo

C2 - 25174598

AN - SCOPUS:84906888413

VL - 15

SP - 442

EP - 451

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 7-8

ER -